The pathologic response of resected synovial sarcomas to hyperthermic isolated limb perfusion with melphalan and TNF-α: A comparison with the whole group of resected soft tissue sarcomas

World Journal of Surgical Oncology

Volumn 11, Issue , 2013, Pages 1-7

  Schwindenhammer, Benjamin ^a   Podleska, Lars Erik ^a   Kutritz, Andrea ^a   Bauer, Sebastian ^a   Sheu, Sien Yi ^a   Taeger, Georg ^a   Schmid, Kurt Werner ^a   Grabellus, Florian ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Isolated limb perfusion; Soft tissue sarcomas; Synovial sarcomas; Tumor regression; Tumor response

Indexed keywords

MELPHALAN; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; ALKYLATING AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; COHORT ANALYSIS; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; HYPERTHERMIC ISOLATED LIMB PERFUSION; HYPERTHERMIC THERAPY; LIMB PERFUSION; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; TREATMENT RESPONSE; TUMOR LOCALIZATION; TUMOR REGRESSION; TUMOR VOLUME; CANCER STAGING; CHILD; FOLLOW UP; LIMB; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PERFUSION; PROGNOSIS; REGIONAL PERFUSION; SARCOMA; YOUNG ADULT; SARCOMA, SYNOVIAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; CHILD; COHORT STUDIES; COMBINED MODALITY THERAPY; EXTREMITIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTHERMIA, INDUCED; MALE; MELPHALAN; MIDDLE AGED; NEOPLASM STAGING; PERFUSION; PROGNOSIS; SARCOMA; SARCOMA, SYNOVIAL; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84882588096     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-11-185     Document Type: Article

References (48)

1. The ESMO / European Sarcoma Network Working Group Soft tissue and visceral sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012, 23(Suppl 7):vii92-vii99. The ESMO / European Sarcoma Network Working Group.
2. Grunhagen DJ, de Wilt JH, ten Hagen TL, Eggermont AM. Technology insight: utility of TNF-α-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities. Nat Clin Pract Oncol 2006, 3:94-103.
3. Deroose JP, Burger JW, van Geel AN, den Bakker MA, de Jong JS, Eggermont AM, Verhoef C. Radiotherapy for soft tissue sarcomas after isolated limb perfusion and surgical resection: essential for local control in all patients?. Ann Surg Oncol 2011, 18:321-327. 3032224, 21049306.
4. Muret J, Yacoub M, Terrier P, Drusch F, Laplanche A, Gaudin C, Richon C, Le Pechoux C, Le Cesne A, Lejeune FJ, Tursz T, Fouret P, Bonvalot S, Chouaib S. p53 status correlates with histopathological response in patients with soft tissue sarcomas treated using isolated limb perfusion with TNF-alpha and melphalan. Ann Oncol 2008, 19:793-800.
5. Thijssens KM, van Ginkel RJ, Pras E, Suurmeijer AJ, Hoekstra HJ. Isolated limb perfusion with tumor necrosis factor α and melphalan for locally advanced soft tissue sarcoma: the value of adjuvant radiotherapy. Ann Surg Oncol 2006, 13:518-524. 10.1245/ASO.2006.02.005, 16485147.
6. Pennacchioli E, Deraco M, Mariani L, Fiore M, Mussi C, Collini P, Olmi P, Casali PG, Santinami M, Gronchi A. Advanced extremity soft tissue sarcoma: prognostic effect of isolated limb perfusion in a series of 88 patients treated at a single institution. Ann Surg Oncol 2007, 14:553-559. 10.1245/s10434-006-9251-1, 17122991.
7. Kettelhack C, Wickede M, Vogl T, Schneider U, Hohenberger P. 31Phosphorus-magnetic resonance spectroscopy to assess histologic tumor response noninvasively after isolated limb perfusion for soft tissue tumors. Cancer 2002, 94:1557-1564. 10.1002/cncr.10361, 11920514.
8. Noorda EM, Vrouenraets BC, Nieweg OE, van Coevorden F, van Slooten GW, Kroon BB. Isolated limb perfusion with tumor necrosis factor-α and melphalan for patients with unresectable soft tissue sarcoma of the extremities. Cancer 2003, 98:1483-1490. 10.1002/cncr.11648, 14508836.
9. Grabellus F, Kraft C, Sheu-Grabellus SY, Bauer S, Podleska LE, Lauenstein TC, Pottgen C, Konik MJ, Schmid KW, Taeger G. Tumor vascularization and histopathologic regression of soft tissue sarcomas treated with isolated limb perfusion with TNF-α and melphalan. J Surg Oncol 2011, 103:371-379. 10.1002/jso.21724, 21400518.
10. Issakov J, Merimsky O, Gutman M, Kollender Y, Lev-Chelouche D, Abu-Abid S, Lifschitz-Mercer B, Inbar M, Klausner JM, Meller I. Hyperthermic isolated limb perfusion with tumor necrosis factor-α and melphalan in advanced soft-tissue sarcomas: histopathological considerations. Ann Surg Oncol 2000, 7:155-159. 10.1007/s10434-000-0155-1, 10761796.
11. Stein U, Jurchott K, Schlafke M, Hohenberger P. Expression of multidrug resistance genes MVP, MDR1, and MRP1 determined sequentially before, during, and after hyperthermic isolated limb perfusion of soft tissue sarcoma and melanoma patients. J Clin Oncol 2002, 20:3282-3292. 10.1200/JCO.2002.01.003, 12149303.
12. Olieman AF, van Ginkel RJ, Hoekstra HJ, Mooyaart EL, Molenaar WM, Koops HS. Angiographic response of locally advanced soft-tissue sarcoma following hyperthermic isolated limb perfusion with tumor necrosis factor. Ann Surg Oncol 1997, 4:64-69. 10.1007/BF02316812, 8985519.
13. Plaat BE, Molenaar WM, Mastik MF, Koudstaal J, Van Den Berg E, Koops HS, Hoekstra HJ. Hyperthermic isolated limb perfusion with tumor necrosis factor-α and melphalan in patients with locally advanced soft tissue sarcomas: treatment response and clinical outcome related to changes in proliferation and apoptosis. Clin Cancer Res 1999, 5:1650-1657.
14. Komdeur R, Plaat BE, Hoekstra HJ, Molenaar WM, Hollema H, Van Den Berg E, Mastik MF, van der Graaf WT. Expression of P-glycoprotein, multidrug resistance-associated protein 1, and lung resistance-related protein in human soft tissue sarcomas before and after hyperthermic isolated limb perfusion with tumor necrosis factor-α and melphalan. Cancer 2001, 91:1940-1948. 10.1002/1097-0142(20010515)91:10<1940::AID-CNCR1217>3.0.CO;2-3, 11346877.
15. Deroose JP, van Geel AN, Burger JW, Eggermont AM, Verhoef C. Isolated limb perfusion with TNF-alpha and melphalan for distal parts of the limb in soft tissue sarcoma patients. J Surg Oncol 2012, 105:563-569. 10.1002/jso.22121, 22020863.
16. van Rijswijk CS, Geirnaerdt MJ, Hogendoorn PC, Peterse JL, van Coevorden F, Taminiau AH, Tollenaar RA, Kroon BB, Bloem JL. Dynamic contrast-enhanced MR imaging in monitoring response to isolated limb perfusion in high-grade soft tissue sarcoma: initial results. Eur Radiol 2003, 13:1849-1858. 10.1007/s00330-002-1785-4, 12942285.
17. van Ginkel RJ, Hoekstra HJ, Pruim J, Nieweg OE, Molenaar WM, Paans AM, Willemsen AT, Vaalburg W, Koops HS. FDG-PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma. J Nucl Med 1996, 37:984-990.
18. Been LB, Suurmeijer AJ, Elsinga PH, Jager PL, van Ginkel RJ, Hoekstra HJ. 18F-fluorodeoxythymidine PET for evaluating the response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcomas. J Nucl Med 2007, 48:367-372.
19. Vanel D, Bonvalot S, Guinebretiere JM, Petrow P, Dromain C, Caillet H. MR imaging in the evaluation of isolated limb perfusion: a prospective study of 18 cases. Skeletal Radiol 2004, 33:150-156. 10.1007/s00256-003-0726-x, 14747961.
20. Eggermont AM, Schraffordt KH, Lienard D, Kroon BB, van Geel AN, Hoekstra HJ, Lejeune FJ. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 1996, 14:2653-2665.
21. Eggermont AM, Schraffordt KH, Klausner JM, Kroon BB, Schlag PM, Lienard D, van Geel AN, Hoekstra HJ, Meller I, Nieweg OE, Kettelhack C, Ben-Ari G, Pector JC, Lejeune FJ. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996, 224:756-764. 10.1097/00000658-199612000-00011, 1235474, 8968230.
22. Fletcher CDM, Unni KK, Mertens FE. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Soft Tissue and Bone 2002, Lyon: IARC Press.
23. Salzer-Kuntschik M, Delling G, Beron G, Sigmund R. Morphological grades of regression in osteosarcoma after polychemotherapy - study COSS 80. J Cancer Res Clin Oncol 1983, 106(Suppl):21-24.
24. Tamborini E, Agus V, Perrone F, Papini D, Romano R, Pasini B, Gronchi A, Colecchia M, Rosai J, Pierotti MA, Pilotti S. Lack of SYT-SSX fusion transcripts in malignant peripheral nerve sheath tumors on RT-PCR analysis of 34 archival cases. Lab Invest 2002, 82:609-618. 10.1038/labinvest.3780455, 12004001.
25. Casali PG. Histology- and non-histology-driven therapy for treatment of soft tissue sarcomas. Ann Oncol 2012, 23(Suppl 10):x167-x169. 10.1093/annonc/mds349, 22987955.
26. Eilber FC, Dry SM. Diagnosis and management of synovial sarcoma. J Surg Oncol 2008, 97:314-320. 10.1002/jso.20974, 18286474.
27. Deshmukh R, Mankin HJ, Singer S. Synovial sarcoma: the importance of size and location for survival. Clin Orthop Relat Res 2004, 419:155-161.
28. Guillou L, Benhattar J, Bonichon F, Gallagher G, Terrier P, Stauffer E, Somerhausen NS, Michels JJ, Jundt G, Vince DR, Taylor S, Genevay M, Collin F, Trassard M, Coindre JM. Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. J Clin Oncol 2004, 22:4040-4050. 10.1200/JCO.2004.11.093, 15364967.
29. Shi W, Indelicato DJ, Morris CG, Scarborough MT, Gibbs CP, Zlotecki RA. Long-term treatment outcomes for patients with synovial sarcoma: a 40-year experience at the University of Florida. Am J Clin Oncol 2013, 36:83-88. 10.1097/COC.0b013e31823fe450, 22270107.
30. Trassard M, Le Doussal V, Hacene K, Terrier P, Ranchere D, Guillou L, Fiche M, Collin F, Vilain MO, Bertrand G, Jacquemier J, Sastre-Garau X, Bui NB, Bonichon F, Coindre JM. Prognostic factors in localized primary synovial sarcoma: a multicenter study of 128 adult patients. J Clin Oncol 2001, 19:525-534.
31. Ferrari A, Gronchi A, Casanova M, Meazza C, Gandola L, Collini P, Lozza L, Bertulli R, Olmi P, Casali PG. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer 2004, 101:627-634. 10.1002/cncr.20386, 15274077.
32. Cormier JN, Langstein HN, Pisters PW. Preoperative therapy for soft tissue sarcoma. Cancer Treat Res 2004, 120:43-63. 10.1007/1-4020-7856-0_3, 15217217.
33. Weitz J, Antonescu CR, Brennan MF. Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time. J Clin Oncol 2003, 21:2719-2725. 10.1200/JCO.2003.02.026, 12860950.
34. Jaffe CC. Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol 2006, 24:3245-3251. 10.1200/JCO.2006.06.5599, 16829648.
35. Eggermont AM, de Wilt JH, ten Hagen TL. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol 2003, 4:429-437. 10.1016/S1470-2045(03)01141-0, 12850194.
36. Deroose JP, Eggermont AM, van Geel AN, Burger JW, den Bakker MA, de Wilt JH, Verhoef C. Long-term results of tumor necrosis factor α- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas. J Clin Oncol 2011, 29:4036-4044. 10.1200/JCO.2011.35.6618, 21931039.
37. Grabellus F, Stylianou E, Umutlu L, Sheu SY, Lehmann N, Taeger G, Lauenstein TC. Size-based clinical response evaluation is insufficient to assess clinical response of sarcomas treated with isolated limb perfusion with TNF-α and melphalan. Ann Surg Oncol 2012, 19:3375-3385. 10.1245/s10434-012-2408-1, 22622472.
38. Ladanyi M, Antonescu CR, Leung DH, Woodruff JM, Kawai A, Healey JH, Brennan MF, Bridge JA, Neff JR, Barr FG, Goldsmith JD, Brooks JS, Goldblum JR, Ali SZ, Shipley J, Cooper CS, Fisher C, Skytting B, Larsson O. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res 2002, 62:135-140.
39. Kawai A, Woodruff J, Healey JH, Brennan MF, Antonescu CR, Ladanyi M. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med 1998, 338:153-160. 10.1056/NEJM199801153380303, 9428816.
40. Grabellus F, Kraft C, Sheu SY, Ebeling P, Bauer S, Lendemans S, Schmid KW, Taeger G. Evaluation of 47 soft tissue sarcoma resection specimens after isolated limb perfusion with TNF-α and melphalan: histologically characterized improved margins correlate with absence of recurrences. Ann Surg Oncol 2009, 16:676-686. 10.1245/s10434-008-0277-4, 19130134.
41. Ferguson PC. Surgical considerations for management of distal extremity soft tissue sarcomas. Curr Opin Oncol 2005, 17:366-369. 10.1097/01.cco.0000166651.38417.c8, 15933470.
42. Eilber FC, Rosen G, Eckardt J, Forscher C, Nelson SD, Selch M, Dorey F, Eilber FR. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J Clin Oncol 2001, 19:3203-3209.
43. Gaynor JJ, Tan CC, Casper ES, Collin CF, Friedrich C, Shiu M, Hajdu SI, Brennan MF. Refinement of clinicopathologic staging for localized soft tissue sarcoma of the extremity: a study of 423 adults. J Clin Oncol 1992, 10:1317-1329.
44. Colterjohn NR, Davis AM, O'Sullivan B, Catton CN, Wunder JS, Bell RS. Functional outcome in limb-salvage surgery for soft tissue tumours of the foot and ankle. Sarcoma 1997, 1:67-74. 10.1080/13577149778326, 2395356, 18521204.
45. Jyothirmayi R, Sittampalam Y, Harmer C. Soft tissue sarcoma of the hand or foot: conservative surgery and radiotherapy. Sarcoma 1999, 3:17-24. 10.1080/13577149977820, 2395404, 18521260.
46. Okunieff P, Suit HD, Proppe KH. Extremity preservation by combined modality treatment of sarcomas of the hand and wrist. Int J Radiat Oncol Biol Phys 1986, 12:1923-1929. 10.1016/0360-3016(86)90126-4, 3771312.
47. Talbert ML, Zagars GK, Sherman NE, Romsdahl MM. Conservative surgery and radiation therapy for soft tissue sarcoma of the wrist, hand, ankle, and foot. Cancer 1990, 66:2482-2491. 10.1002/1097-0142(19901215)66:12<2482::AID-CNCR2820661207>3.0.CO;2-L, 2249188.
48. Zeytoonjian T, Mankin HJ, Gebhardt MC, Hornicek FJ. Distal lower extremity sarcomas: frequency of occurrence and patient survival rate. Foot Ankle Int 2004, 25:325-330.